Upload
others
View
3
Download
0
Embed Size (px)
Citation preview
Prevention and early
treatment ofCOVID-19
FOUNDING MEMBERS
• March 2020• FLCCC formed by leading
Critical Care specialists• Non-profit • Mission: Develop effective
COVID-19 treatment protocols
• Prevent COVID-19 transmission
• Improve patient outcomes
Hospital protocol
created by the FLCCC in
March 2020
December 4, 2020A CALL-TO-ACTION
IN A TIME OF A NATIONAL AND GLOBAL HEALTH
CRISIS
NATIONAL CALL-TO-ACTIONVaccines are coming,
but they are onlypart of the solution.
Electronic Press Kit:flccc.net
FRONT LINE COVID-19 CRITICAL CARE ALLIANCEPROPHYLAXIS & TREATMENT PROTOCOLS FOR COVID-19
PROPHYLAXIS PROTOCOL
lvermectin Prophylaxis for high risk individuals 0.2 mg/kg* — one dose on day 1 and day 3, then take
one dose every 4 weeks
Post COVID-19 exposure prophylaxis** 0.2 mg/kg* — one dose on day 1 and day 3
Vitamin D3 1,000–3,000 IU/day
Vitamin C 1,000 mg twice a day
Quercetin 250 mg/day
Zinc 50 mg/day
Melatonin 6 mg before bedtime (causes drowsiness)
EARLY OUTPATIENT PROTOCOL***
lvermectin 0.2 mg/kg* — one dose on day 1 and day 3
Vitamin D3 4,000 IU/day
Vitamin C 2,000 mg 2–3 times daily
Quercetin 250 mg twice a day
Zinc 100 mg/day
Melatonin 10 mg before bedtime
Aspirin 325 mg/day (unless contraindicated)
* ≈ 0.09 mg/lb per dose (take on an empty stomach with water). Example for a person of 60 kg (body weight): 60 kg × 0.2 mg = 12 mg — please see conversion table (kg lbs) on page 2 to calculate the appropriate ivermectin dose.
** To use if a household member is COVID-19 positive, or you have prolonged exposure to a COVID-19 positive patient without wearing a mask
*** For late phase — hospitalized patients — see the FLCCC’s MATH+ Hospital Treat ment Protocol for COVID-19 on www.flccc.net
Page 1/2
Please regard our disclaimer and further information on page 2 of this document.
www.flccc.net © 2020 FLCCC Alliance · I-MASK+ Protocol v5 · Nov. 28, 2020 Layout
& t
ypes
etti
ng
by
rau
mfi
sch
.de/
sig
n
Must wear cloth, surgical,
or N95 mask (without valve)
in all indoor spaces with non-
household persons.
Must wear a N95 mask
(without valve) during pro-
longed exposure to non-
household persons in any
confined, poorly ventilated
area.
WEAR MASKS
KEEP DISTANCE
Until the end of the Covid-19
crisis, we recommend keep -
ing a minimum dis tance of
approx. 2 m / 6 feet in public
from people who are not
from your own household.
WASH HANDS
We recommend, after a stay
during and after outings
from home (shopping, sub-
way etc.), a thorough hand
cleaning (20–30 sec. with
soap), or also to use a hand
disinfectant in between.
Behavioral Prophylaxis
PROPHYLAXIS & EARLY OUTPATIENT TREATMENT PROTOCOL FOR COVID-19
FRONT LINE COVID-19 CRITICAL CARE ALLIANCEPROPHYLAXIS & TREATMENT PROTOCOLS FOR COVID-19
PROPHYLAXIS PROTOCOL
lvermectin Prophylaxis for high risk individuals 0.2 mg/kg* — one dose on day 1 and day 3,
then take one dose every 4 weeks
Post COVID-19 exposure prophylaxis** 0.2 mg/kg* — one dose on day 1 and day 3
Vitamin D3 1,000–3,000 IU/day
Vitamin C 1,000 mg twice a day
Quercetin 250 mg/day
Zinc 50 mg/day
Melatonin 6 mg before bedtime (causes drowsiness)
EARLY OUTPATIENT PROTOCOL***
lvermectin 0.2 mg/kg* — one dose on day 1 and day 3
Vitamin D3 4,000 IU/day
Vitamin C 2,000 mg 2–3 times daily
Quercetin 250 mg twice a day
Zinc 100 mg/day
Melatonin 10 mg before bedtime
Aspirin 325 mg/day (unless contraindicated)
* ≈ 0.09 mg/lb per dose (take on an empty stomach with water). Example for a person of 60 kg (body weight): 60 kg × 0.2 mg = 12 mg — please see conversion table (kg lbs) on page 2 to calculate the appropriate ivermectin dose.
** To use if a household member is COVID-19 positive, or you have prolonged exposure to a COVID-19 positive patient without wearing a mask
*** For late phase — hospitalized patients — see the FLCCC’s MATH+ Hospital Treat ment Protocol for COVID-19 on www.flccc.net
Page 1/2
Please regard our disclaimer and further information on page 2 of this document.
www.flccc.net © 2020 FLCCC Alliance · I-MASK+ Protocol v5 · Nov. 28, 2020 Layout
& t
ypes
etti
ng
by
rau
mfi
sch
.de/
sig
n
Must wear cloth, surgical,
or N95 mask (without valve)
in all indoor spaces with non-
household persons.
Must wear a N95 mask
(without valve) during pro-
longed exposure to non-
household persons in any
confined, poorly ventilated
area.
WEAR MASKS
KEEP DISTANCE
Until the end of the Covid-19
crisis, we recommend keep -
ing a minimum dis tance of
approx. 2 m / 6 feet in public
from people who are not
from your own household.
WASH HANDS
We recommend, after a stay
during and after outings
from home (shopping, sub-
way etc.), a thorough hand
cleaning (20–30 sec. with
soap), or also to use a hand
disinfectant in between.
Behavioral Prophylaxis
PROPHYLAXIS & EARLY OUTPATIENT TREATMENT PROTOCOL FOR COVID-19
• 40-year-old anti-parasitic drug• Discovery awarded Nobel Prize in 2015 • On the W.H.O.’s list of “essential medicines.”
Used safely by 3.7 billionpeople worldwide.
High activity against COVID19• Pre-Exposure• Post-Exposure• Early Symptoms• Late Stage Disease
New and compelling data has emerged since August—the last time the N.I.H.
updated their recommendations
Electronic Press Kit:flccc.net
Studies show consistent,
reproducible efficacy of Ivermectin.
Prophylaxis Trials of > 1,100 patients•3 Randomized Controlled Trials
•1 Observational Trial
0,00%
15,00%
30,00%
45,00%
60,00%
75,00%
Ivermectin Prophylaxis, N=228 No Prophlaxis, N=112
7.4%
58.4%Percentage
of household contacts with
COVID-19 symptoms
Shouman W. NCT04422561 p < .05
Prophylaxis of household contacts of COVID-19 patients Randomized, Controlled Trial
Zagazig University, Egypt
0,
17,5
35,
52,5
70,
Ivermectin Prophylaxis, N=91 No Prophylaxis, N=281
16.4%
60.8%
Behera P et al., https://www.medrxiv.org/content/10.1101/2020.10.29.20222661v1.full (2020)
Prophylaxis of health care workers studyObservational Controlled Trial
All India Institute of Medical Sciences
Percentage of health care
workers who contracted
COVID-19
0,
0,03
0,05
0,08
0,1
0,13
Ivermecin Prophylaxis, N=100 No Prophylaxis, N=100
A. Elgazzar et al., https://www.researchsquare.com/article/rs-100956/v2 (2020)
2.0%
10.0%
Percentage of health care and
household contacts who
contracted COVID-19
Prophylaxis of household and health care worker contacts of COVID-19 patients
Randomized Controlled Trial
Carvallo H. https://clinicaltrials.gov/ct2/show/NCT04425850 (2020)
0,
0,03
0,06
0,09
0,12
Ivermectin Prophlaxis, N=131No Ivermectin Prophylaxis, N=98
0.0%
11.2%
Percentage of healthy citizens who contracted COVID-19 after
28 days
Prophylaxis of 229 Heathy CitizensRandomized Controlled Trial – Argentina
Long Term Care Facility A Long Term Care Facility B+C+D
Outpatient Trials – 500 Patients • 3 Randomized Controlled Trials
• Large Case Series
Hospitalized Patient Trials4 Randomized Controlled Trials > 800 patients
4 Observational Controlled Trials > 2000 patients
All available clinical trial results
show major benefits of Ivermectin
in prevention and treatment
Deaths in patients over 60 among 8 Peruvian states after deploying mass ivermectin treatment
Decreases in COVID-19 Case Fatality Rates in Peruvian patients over 60
PARAGUAY
Electronic Press Kit:flccc.net
NATIONAL CALL-TO-ACTIONNational & Global Health Authorities:
Review Recent Clinical Trials Evidence Demonstrating Clinical Benefits of IVERMECTIN
Failed and successful Rx for COVID-19 by phase of illness*
* Based on Randomized Controlled Trials
flccc.net
NATIONAL CALL-TO-ACTIONFollowing swift validation of evidence,
health authorities are urged to issue guidelines for health care providers to prescribe
IVERMECTIN
I-MASK+ will change the face of this disease worldwide.
Electronic Press Kit:flccc.net